Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2026)

Sarepta Therapeutics' Raw Materials history runs 11 years deep, the most recent figure standing at $137.0 million for Q1 2026.

• On a quarterly basis, Raw Materials fell 54.19% year-over-year to $137.0 million in Q1 2026; TTM through Mar 2026 was $137.0 million, a 54.19% decrease from a year earlier, with the FY2025 full-year figure at $141.3 million, down 49.55% from the prior year.
• Raw Materials eased to $137.0 million in Q1 2026 per SRPT's latest filing, from $141.3 million in the prior quarter.
• Across five years, Raw Materials topped out at $325.5 million in Q3 2025 and bottomed at $58.0 million in Q3 2022.
• The 5-year median for Raw Materials is $167.2 million (2024), against an average of $189.1 million.
• Across the five-year window, Raw Materials soared 430.0% in 2022 and tumbled 65.56% in 2023, its largest moves.
• Year by year, Raw Materials stood at $59.2 million in 2022, then surged by 126.36% to $134.0 million in 2023, then jumped by 109.05% to $280.0 million in 2024, then sank by 49.55% to $141.3 million in 2025, then fell by 3.06% to $137.0 million in 2026.
• Per Business Quant, the three latest SRPT Raw Materials figures stand at $137.0 million (Q1 2026), $141.3 million (Q4 2025), and $325.5 million (Q3 2025).